
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health has demonstrated strong market leadership in its companion animal products, with Simparica Trio maintaining over a 50% market share, while the projected increase for Credelio Quattro's market share to 16.8% by 2026 reflects significant growth potential. The Advantage Family and Seresto product lines have also shown impressive year-over-year growth of 33% and 28%, respectively, as of the third quarter of 2025, indicating robust demand and consistent performance. These trends suggest a positive trajectory for Elanco's sales and market presence, supporting an optimistic outlook for the company's financial health.
Bears say
Elanco Animal Health has raised concerns regarding its refinancing efforts, particularly in light of high interest rates exemplified by Dentsply Sirona's recent $550 million offering at 8.375%, potentially impacting earnings growth in 2026. Additionally, while the company's revenue has increased by approximately 50%, its EBITDA margin has declined by a couple of hundred basis points, indicating potential issues with profitability. Although the company reported a $28 million EBITDA outperformance in the second quarter, the combination of refinancing risks and margin compression poses significant challenges for Elanco's financial outlook.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares